- Home
- DRRX vs IGC Comparison
DRRX vs IGC Comparison
Compare DRRX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- IGC
- Stock Information
- Founded
- DRRX 1998
- IGC 2005
- Country
- DRRX United States
- IGC United States
- Employees
- DRRX N/A
- IGC N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- IGC Health Care
- Exchange
- DRRX Nasdaq
- IGC Nasdaq
- Market Cap
- DRRX 26.3M
- IGC 29.4M
- IPO Year
- DRRX 2000
- IGC N/A
- Fundamental
- Price
- DRRX $0.80
- IGC $0.30
- Analyst Decision
- DRRX Buy
- IGC Strong Buy
- Analyst Count
- DRRX 2
- IGC 2
- Target Price
- DRRX $5.00
- IGC $3.75
- AVG Volume (30 Days)
- DRRX 54.3K
- IGC 399.9K
- Earning Date
- DRRX 03-26-2025
- IGC 03-04-2025
- Dividend Yield
- DRRX N/A
- IGC N/A
- EPS Growth
- DRRX N/A
- IGC N/A
- EPS
- DRRX N/A
- IGC N/A
- Revenue
- DRRX $8,594,000.00
- IGC $1,236,000.00
- Revenue This Year
- DRRX $54.32
- IGC N/A
- Revenue Next Year
- DRRX N/A
- IGC $13.38
- P/E Ratio
- DRRX N/A
- IGC N/A
- Revenue Growth
- DRRX N/A
- IGC 1.64
- 52 Week Low
- DRRX $0.70
- IGC $0.27
- 52 Week High
- DRRX $1.88
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- DRRX 49.63
- IGC 38.51
- Support Level
- DRRX $0.73
- IGC $0.29
- Resistance Level
- DRRX $0.83
- IGC $0.33
- Average True Range (ATR)
- DRRX 0.05
- IGC 0.01
- MACD
- DRRX 0.01
- IGC -0.00
- Stochastic Oscillator
- DRRX 63.57
- IGC 15.00
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.